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Highlights 
1. Choline PET/CT remains a useful tool for the detection of prostate cancer recurrence. 
2. The sensitivity of choline PET/CT to detect recurrence can be improved by using appropriate 
use criteria. 
3. Removal of dynamic and delayed acquisition phases reduces study time without adversely 
affecting accuracy. 
Abstract 
Purpose: To evaluate the efficacy of single time-point whole-body Fluorine-18 Choline PET-CT 
compared to a triple-phase acquisition protocol in the detection of prostate carcinoma recurrence. 
 
Materials and Methods: Consecutive Choline PET-CT studies performed at a single tertiary referral 
centre in patients with biochemical recurrence of prostate carcinoma between September 2012 and 
March 2017 were retrospectively reviewed. The indication for the study, scanning protocol used, 
imaging findings, whether management was influenced by the PET-CT and subsequent patient 
outcome were recorded.  
 
Results: 91 scans were performed during the study period; 42 were carried out using a triple-phase 
scanning protocol (dynamic pelvic imaging for 20 minutes after tracer injection, half-body acquisition 
at 60 minutes and delayed pelvic scan at 90 minutes) between 2012 and August 2015. Subsequently 
following interim review of diagnostic performance, a streamlined protocol and appropriate-use 
criteria were introduced. 49 scans were carried out using the single-phase scanning protocol between 
2015 and 2017. 29 (69%) of the triple-phase studies were positive for recurrence compared to 38 (78%) 
of the single-phase studies. Only one patient who had a single-phase study would have benefited from 
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a dynamic acquisition, they have required no further treatment or imaging and are currently under 
PSA surveillance.  
 
Conclusion: Choline PET-CT remains a useful tool for the detection of prostate recurrence when used 
in combination with appropriate-use criteria. Removal of dynamic and delayed acquisition phases 
reduces study time without adversely affecting accuracy. Benefits include shorter imaging time which 
improves patient comfort, reduced cost and improved scanner efficiency. 
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Introduction 
Prostate carcinoma is the second most common malignancy affecting men worldwide with 1.7 million 
new cases expected by 2030 if the current trend continues.1 A third of patients develop recurrence 
following radical treatment.1 Positron emission tomography – computed tomography (PET-CT) is not 
routinely used in the initial work up of patients with suspected prostate malignancy but has been 
demonstrated to have, in a meta-analysis by Evangelista et al., a pooled sensitivity of 49.2% (95% CI: 
39.9%-58.4%) and specificity of 95% (95% CI: 92.0% -97.1%) for the initial staging of lymph nodes.2  
The use of PET-CT has become more widely accepted in the investigation of patients with biochemical 
recurrence. There is evidence for the use of multi-parametric magnetic resonance imaging (mpMRI), 
which can aid in the detection of local recurrence, however, PET-CT allows both local recurrence and 
distant metastases to be identified.3 There is an established role for Choline PET-CT in patients who 
have undergone radical treatment and have evidence of biochemical failure (rising prostate specific 
antigen, PSA), when there is negative or equivocal conventional imaging and the patient is suitable for 
further salvage treatment.4,5 Choline accumulates in tumours which have a low glucose metabolism 
as it is an analogue for the biosynthesis of the cell membrane.6, 7, 8, 9 The sensitivity and specificity of 
Choline PET-CT for detecting all sites of recurrence has been reported to be 85.6% (95% CI: 82.9%–
88.1%) and 92.6% (95% CI: 90.1%–94.6%), respectively.10 
 
A rapid PSA doubling time (< 6 months), increasing PSA level despite androgen deprivation therapy, 
PSA >2 ng/ml, a high Gleason score or high PSA nadir after radical prostatectomy increase the 
likelihood of a positive Choline PET-CT study.11, 12, 13 
 
Choline PET-CT has traditionally been performed using a triple-phase scanning protocol, however, 
there is no universally agreed protocol with centres performing either a triple-phase protocol or a 
variation where either the delayed or dynamic phase is excluded. During the triple-phase protocol, 
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patients have an early dynamic acquisition through the pelvis, followed by a standard half-body scan 
from skull base to upper thighs 60 minutes after tracer injection and a delayed pelvic acquisition. The 
rationale for this protocol is firstly to differentiate tracer uptake within the prostate from physiological 
urinary accumulation and secondly to determine the uptake characteristics of lymph nodes to aid in 
classification between benign or malignant pathologies.14, 15, 16, 17  This, however, does mean that 
patients spend a longer time within the department which is inconvenient and reduces patient 
throughput.  
 
More recently the use of prostate specific membrane antigen (PSMA) PET-CT has been reported to 
have greater sensitivity in the detection of prostate carcinoma when compared to Choline PET-CT.18 
However, this is not currently funded by NHS England and is only available in very few centres in the 
United Kingdom. There is also a paucity of cost-effectiveness data supporting the widespread 
transition to this technique. Use of Choline PET-CT in this clinical scenario is however, in the list of 
indications funded by NHS England and more readily available at a range of specialist centres across 
England. For the foreseeable future in the UK, there is still likely to be a valuable role for Choline PET-
CT in the detection of site of recurrence and formation of management plans. 
 
The purpose of this study was to evaluate the utility of a streamlined (single-phase) scanning protocol 
for Choline PET-CT as part of a quality improvement process and secondly to review the positive 
detection rate of Choline PET-CT using appropriate-use criteria at our institution in comparison to 
published data. 
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Methods 
A retrospective review of consecutive Choline PET-CT studies undertaken at a single institution 
between September 2012 and March 2017 was performed. The indication for the study, scanning 
protocol used, imaging findings, whether management was influenced by the PET-CT and patient 
outcome were all recorded.  
 
Appropriate Use Criteria 
Referring clinicians were provided with appropriate use criteria for Choline PET-CT referrals which 
included:  
1.! Assessment of patients with biochemical relapse after prior local treatment with curative 
intent (radical prostatectomy, radiotherapy or brachytherapy) to differentiate between local, 
loco-regional and systemic relapse; 
2.! Serum PSA > 1 ng/mL and results of the scan will influence patient management e.g. salvage 
radiotherapy or prostatectomy would be performed if localized recurrence is confirmed; 
3.! Studies are more likely to have a higher diagnostic utility if there is a high Gleason score, a 
rapid PSA doubling time (< 6 months), increasing PSA level despite androgen deprivation 
therapy or high PSA nadir after radical prostatectomy; 
4.! The study may not be clinically useful if the PSA is <2 ng/ml. 
 
Appropriate use criteria were introduced at the time as the single-phase protocol. 
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Scanning Protocol  
Triple-phase Acquisition 
PET-CT was performed on a 64 slice Discovery 690 scanner (GE Healthcare, Waukesha, Wisconsin, 
USA). 4 MBq per kilogram of body mass of Fluorine-18 Ethyl-Choline was injected intravenously. A 
dynamic single bed position list mode study was acquired through the pelvis from 0 to 20 minutes 
following injection. At 60 minutes PET images were acquired from skull base to upper thighs. Finally, 
a delayed single bed position pelvic PET was performed at 90 minutes. Low-dose, unenhanced CT was 
also performed: 140 kV; 80 mAs; tube rotation time 0.5s per rotation; pitch 6; 3.75 mm slices 
(matching PET slice thickness). Patients maintained shallow respiration during the examination. 
Images were reconstructed using a standard ordered subset expectation maximization (OSEM) 
algorithm with CT used for attenuation correction. Both non-attenuation corrected and attenuation 
corrected datasets were reconstructed. 
 
Single-phase Acquisition  
PET-CT performed on one of 2 64 slice scanners Discovery 690 and Discovery 710 (GE Healthcare). A 
fixed dose of 350MBq of Fluorine-18 Ethyl-Choline was injected intravenously. At 60 minutes PET 
images were acquired from skull base to upper thighs. Low-dose, unenhanced CT was also performed: 
140 kV; 80 mAs; tube rotation time 0.5s per rotation; pitch 6; 3.75 mm slices (matching PET slice 
thickness). Patients maintained shallow respiration during the examination. Images were 
reconstructed using a standard ordered subset expectation maximization (OSEM) algorithm with CT 
used for attenuation correction. Both non-attenuation corrected and attenuation corrected datasets 
were reconstructed. 
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Image Interpretation  
Images were retrospectively reviewed independently by two dual-trained Consultant Radiologists & 
Nuclear Medicine Physicians with at least 8 years’ experience of PET-CT interpretation, using 
specialised software (Advantage Windows Version 4.5, GE Healthcare). The scans were evaluated 
qualitatively and quantitatively (using maximum standardised uptake value (SUVmax)). If the study 
was performed using triple-phase protocol the dynamic and delayed acquisitions were rated on 
whether they contributed to scan interpretation on a per lesion and per patient basis independently 
and any disagreements were reviewed and agreed in consensus.  
 
Data Analysis 
PSA doubling time and PSA velocity were calculated using an online calculator available at 
http://www.doubling-time.com/compute-PSA-doubling-time.php. The difference in PSA, PSA velocity 
and PSA doubling time between negative and positive studies were analysed using Mann Whitney U 
tests. All statistical analysis was performed using IBM SPSS Statistics (Version 22, Armonk, New York, 
USA). 
 
Results 
84 patients were scanned during the study period. Mean patient age was 68 years (range 48 - 80 years). 
91 Choline PET-CT scans were performed, most were carried out following rising PSA post treatment 
(n= 82) (Table 1). Pre-scan PSA values were available for 76 patients. The median pre-scan PSA value 
was 2.58ng/ml (range 0.06 - 147ng/ml), the median time from last PSA to Choline PET-CT was 40.5 
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days (range 2 to 188 days), the median PSA doubling time was 0.51 years (range -0.96 - 12.2ng/ml) 
and the median PSA velocity was 0.11ng/ml/month (range -3.62 - 1.48ng/ml/month).  
There was a significant difference in PSA velocity for positive compared to negative studies, median 
0.11ng/ml/month and 0.05 for positive and negative studies respectively, (p = 0.038) and pre-test PSA 
3.2ng/ml and 1.3ng/ml for positive and negative scans respectively, (p=0.002). There was no 
significant difference in PSA doubling time between positive and negative studies.  
 
42 (46%) Choline PET-CT studies were carried out using the triple-phase scanning protocol. Of these, 
29 (69%) studies were positive for recurrence: 11 local recurrence, 10 nodal relapse and 8 with distant 
metastases. One study benefited from the dynamic acquisition (Figure 1) and one study benefited 
from either the dynamic or delayed acquisition (Figure 2). Four patients who had a triple-phase study 
had equivocal findings on Choline PET-CT (Table 2). Of these, two had biopsy proven metastases, one 
patient was started on hormone and radiotherapy treatment because of the PET-CT and one patient 
underwent an MRI to evaluate equivocal bone uptake which did not demonstrate a metastasis (Figure 
3), the patient remains disease free following 3 years of follow up.   
 
49 (54%) studies were performed using the single-phase acquisition protocol. Of these studies, 38 
(78%) were positive for recurrence; 10 demonstrating local recurrence, 3 local and nodal disease, 16 
nodal disease, 7 with distant metastases and 2 with local, nodal and metastases. Five patients who 
had a single-phase study had indeterminate findings on the PET-CT. Of these patients, one patient was 
felt to have possible prostatitis but was later proven to have local recurrence, two patients were put 
into a surveillance programme, one patient was started on hormone therapy and one patient with 
indeterminate bone lesions was found to have had previous trauma to the areas after clinical 
correlation (Table 2). Only one of these patients would have benefited from an early dynamic 
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acquisition as they had a focus of activity within the central prostate, which was felt to represent 
physiological urinary activity within the prostatic urethra (Figure 4). They are currently having 
surveillance PSAs with the plan to start hormonal treatment if the PSA continues to rise. One patient 
had two negative Choline PET-CT studies although his PSA was continuing to rise (PSA 0.35ng/ml on 
initial imaging and 3.5ng/ml at the time of the second study, PSA velocity = 0.02 ng/ml/month) with 
the plan for PSA surveillance and hormone therapy if the PSA continued to increase.  
 
The PSA levels of patients with negative or positive studies were not significantly different 
between the single or triple-phase protocols (p=0.501 and p=0.163 respectively) (Figure 5). 
There were six scans which were performed using the single-phase protocol which had a PSA 
of <1ng/ml, three of which were positive. Two of these patients did however have high PSA 
doubling times <6 months. Seven of the patients who had triple-phase studies had PSA levels 
of less than 1ng/ml, four of which were negative. All the triple-phase study patients with PSA 
<1ng/ml had PSA doubling times <6 months.  
 
Discussion 
In other developed nations, Choline PET-CT use in the evaluation of patients with prostate cancer is 
being gradually eclipsed by more sensitive PET tracers targeting PSMA.19 PSMA imaging does have 
some limitations due to PSMA expression not being limited to the prostate, as its name would imply, 
and also there is currently a lack of evidence demonstrating its effect on patient outcome in early 
biochemical recurrence.20 In addition, the amino acid PET tracer, 18F-Fluciclovine, recently approved for 
recurrent prostate cancer imaging, is injected with a short uptake time with relatively low urinary bladder 
activity, circumventing some of the issues posed with the logistics and interpretation of choline scans.21 For a 
variety of economic and logistical reasons these tracers are not currently funded by the National 
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Health Service in the UK. However, there is established funding and infrastructure for Choline PET-CT 
at several specialist centres in England. This study has confirmed that Choline PET-CT remains a useful 
tool in the detection of prostate carcinoma recurrence particularly when used in conjunction with 
appropriate use criteria. Overall 67 of 91 (74%) of studies were positive for recurrence and 
rationalisation of the technique to a single-phase protocol did not lead to a reduction in positive rate 
(78%). A recent meta-analysis incorporating 18 studies with a combined 2,126 participants reported a 
pooled detection rate for Choline PET-CT in prostate cancer of 62% (95% CI 53%-93%). 22   The 
difference in the detection rate is likely due to the variations in referral criteria and clinical indication 
as it has previously been demonstrated that Choline PET-CT studies are more likely to be positive when 
there is rapidly doubling PSA or the PSA is rising despite androgen therapy. 23 , 24  There was no 
significance in PSA doubling times between positive and negative scans in this study but there was a 
statistically significant difference when comparing PSA velocities and pre-test PSA values for patients 
with positive studies when compared with negative ones. The lack of significance in PSA doubling time 
is likely due to the relatively small patient cohort combined with the fact that 50% of patients with a 
PSA doubling time of less than a year have been reported to have recurrence which all leads to a 
degree of error.23 However, this study does highlight the relatively high detection rate if appropriate 
use criteria are used.  
 
The utility of dynamic and delayed imaging has been reported by a number of previous studies in the 
detection of local and distant disease.14, 15, 16, 17, 25, 26 Other groups have reported using a single-phase 
acquisition protocol but with lower positive detection rates than in this study (42.9% - 62%).27,28 The 
variation in the positive detection rates likely reflects the usefulness of appropriate use criteria in 
patient selection. Three of the 91 PET-CT studies (3%) performed in our cohort may have benefited 
from an extra acquisition to differentiate between pathological and physiological uptake, only one of 
these was a patient who had a single-phase acquisition study.  This scan was reported as likely 
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physiological urinary activity within the central prostate and therefore the patient was managed 
conservatively with PSA surveillance. The PSA remained stable and it was concluded that the uptake 
was physiological. 
 
Even if a PET-CT is negative further management can still be derived. One patient had two negative 
PET-CTs but the PSA was continuing to rise (PSA 0.35ng/ml on initial imaging and 3.5ng/ml at the time 
of the second study, PSA velocity = 0.02 ng/ml/month) and therefore was started on hormonal 
treatment as it was felt that the Choline study missed recurrence. This did not have a negative impact 
on the long-term prognosis of the patient. Their PSA remained stable following hormonal treatment 
and there was no further indication of recurrence. In the future, if limited funding becomes available 
for PSMA PET-CT, a sequential imaging approach could be adopted with Choline PET-CT used first-line 
and PSMA PET-CT reserved for negative cases.29  
 
Limitations of this study include the retrospective nature, relatively small cohort size and lack of 
histological validation for the examinations that are reported as positive as not all patients had salvage 
surgery to provide histological evidence of recurrence.  
 
Despite the stated limitations this study has confirmed that streamlining the PET-CT scanning protocol 
from three- to single-phase acquisition reduced study time without adversely affecting accuracy. The 
single-phase protocol has reduced scanning time by approximately a half (from 60 minutes to 30 
minutes), this facilitates increased scanner throughput. More importantly, adherence to appropriate 
use criteria results in a higher detection rate than in prior published series. This quality improvement 
process has added benefits of reduced patient inconvenience, decreased overall cost and improved 
scanner efficiency.   
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Conclusion 
Choline PET-CT remains a useful tool for the detection of prostate recurrence when used in 
combination with appropriate-use criteria. Removal of dynamic and delayed acquisition phases 
reduces study time without adversely affecting accuracy. Benefits include less patient inconvenience, 
reduced cost and improved scanner efficiency. 
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Tables 
 
Indication Number of studies 
Previous radical treatment and now rising PSA 82 
Lesion detected on initial staging, PET-CT to clarify if 
only site of metastases 
4 
Lesion detected on repeat imaging, PET-CT to clarify if 
only site of metastases 
4 
Follow up of previously demonstrated tracer update on 
PET-CT 
1 
 
Table 1: Indications given on the requests for Choline PET-CT  
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Patient Indication PET-CT Finding Outcome 
1 Gleason 7. Previous radical radiotherapy. 
PSA rising 
Diffuse prostate uptake - 
suspected prostatitis  
MRI demonstrated 
recurrence 
2 Brachytherapy and radiotherapy. PSA rising  Focus of activity in the central 
prostate likely urinary. Suspicious 
iliac chain nodes   
PSA surveillance  
3 Brachytherapy and radiotherapy. PSA rising Suspicious for small-volume 
nodal recurrence within left 
common iliac, internal iliac and 
pelvic sidewall lymph nodes. 
Hormone Therapy 
4 Post prostatectomy and salvage 
radiotherapy. Rising PSA  
Equivocal left external iliac lymph 
node with faint uptake 
CT surveillance  
5T Lung metastasis resected. Now single 
metastasis in right posterior 7th rib. Query 
further sites of disease 
 
Indeterminate mediastinal nodal 
tracer uptake 
EBUS demonstrated 
metastatic lymph node 
6T Post prostatectomy and pelvic 
radiotherapy. Rising PSA 
 
Probable localised recurrence 
within a solitary left pelvic 
sidewall node 
Hormone treatment and 
radiotherapy 
7T Brachytherapy and radiotherapy for 
prostate cancer. Rising PSA   
 
Possible early nodal recurrence 
within sub-cm right pelvic 
sidewall nodes 
Lymphadenectomy  - 
metastatic nodes 
8 Sclerotic rib lesions on bone scan. 
 
Tracer avid prostate cancer. The 
tracer negative rib lesions are 
indeterminate 
Rib lesions due to 
previous trauma 
9T Post prostate brachytherapy. Rising PSA Indeterminate focal uptake in the 
region of the right lesser 
trochanter – MR advised 
MRI - No metastasis  
 
Table 2: Indications and patient outcomes for equivocal findings on Choline PET-CT. Key: T= Triple-
phase, EBUS = Endobronchial Ultrasound  
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Figures & Legends 
 
Figure 1: 18F-Choline PET-CT study of a 64 year old patient, who had previously been treated with a 
radical prostatectomy, with suspected recurrent prostate carcinoma. The dynamic study 
demonstrates a focus of uptake within the region of the prostate (A) (arrow), this is demonstrated 
before accumulation of tracer within the urinary bladder as demonstrated on the 60 minute 
acquisition (B) and fused PET-CT (C) (arrowheads). Therefore, this confirms the presence of local 
recurrence.  
 
Figure 2: 18F-Choline PET-CT study of a 69 year old patient with suspected recurrent prostate 
carcinoma. The 60 minute coronal PET and fused PET-CT images demonstrate a focus of uptake 
within the region of the prostate (A and B) (arrows). This is demonstrated to washout on the delayed 
90 minute coronal PET and fused coronal PET-CT (C and D) images (arrowheads) and therefore is 
likely physiological and not recurrence. 
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Figure 3: 18F-Choline PET-CT study of a 67 year old patient with suspected recurrent prostate 
carcinoma. The 60 minute single acquisition axial fused PET-CT (A) and coronal fused PET-CT (B) 
demonstrate a focus of tracer activity within the lesser trochanter of the left femur (arrows). Follow 
up imaging with MR demonstrates normal bone signal on T2 axial (C) and T1 coronal (D) sequences 
(arrowheads).  
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Figure 4: 18F-Choline PET-CT study of a 78 year old patient with suspected recurrent prostate 
carcinoma. The 60 minute single acquisition axial PET (A), axial fused PET-CT (B) and coronal fused 
PET-CT (C) images demonstrate a focus of activity within the central prostate (arrows), this was 
presumed to be from urinary activity. 
 
Figure 5: Comparison of the PSA levels for positive (1) and negative (0) studies between single-phase 
(triangles) and triple-phase studies (circles). Studies where the patient’s PSA was over 12ng/ml were 
excluded, these were all positive scans. 
